Welcome to our dedicated page for Vera Therapeutics SEC filings (Ticker: VERA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vera Therapeutics filings document a Nasdaq-listed biotechnology company developing atacicept for serious immunological diseases, including IgA nephropathy. Form 8-K reports provide financial results, corporate updates, clinical and regulatory disclosures for the atacicept program, and material governance events such as board appointments, executive changes, and compensatory arrangements.
Proxy materials describe annual meeting matters, director elections, auditor ratification, advisory executive compensation votes, board committee structure, and related governance practices. The company’s filings also identify its Class A common stock registered on The Nasdaq Stock Market and disclose equity awards issued under director compensation and inducement grant arrangements.
BlackRock, Inc. filed an amended Schedule 13G reporting beneficial ownership of Class A stock of Vera Therapeutics, Inc. BlackRock reports beneficial ownership of 5,340,522 shares, representing 7.4% of the Class A shares outstanding.
BlackRock has sole voting power over 5,247,811 shares and sole dispositive power over 5,340,522 shares, with no shared voting or dispositive power. Various underlying clients have rights to dividends or sale proceeds, but no individual client holds more than five percent of Vera’s outstanding common shares.
Vera Therapeutics, Inc. director and CEO Marshall Fordyce reported open-market sales of an aggregate 46,250 shares of Class A common stock on July 7, 2026. The shares were sold at weighted-average prices reflecting trade ranges from $40.39 to $43.97 per share.
The filing notes the sales were made under a written trading plan adopted on January 9, 2026 that meets Rule 10b5-1(c) requirements. Following these transactions, Fordyce holds 151,994 shares directly, plus 99,081 shares held by a trust and 122,949 shares held by a GRAT, both reported as indirect ownership.
Vera Therapeutics, Inc. is changing its regulatory leadership. Effective August 3, 2026, Nancy Bowman, M.D., Ph.D. will become the company’s Chief Regulatory Officer. On the same date, current Chief Regulatory Officer William Turner will step down from that role and move into a new position as Special Advisor for Regulatory Affairs.
The company disclosed this leadership transition under the category covering departures and appointments of certain officers.
Vera Therapeutics reported that the U.S. Food and Drug Administration has granted accelerated approval for its drug TRUTAKNA™ (atacicept-vymj) as of July 7, 2026. The therapy is approved to reduce proteinuria in adults with primary immunoglobulin A nephropathy who are at risk for disease progression.
This represents Vera’s transition into a commercial-stage company for IgA nephropathy, with an FDA-cleared product aimed at a serious kidney disease where reducing protein in the urine can help slow long-term damage.
Vera Therapeutics, Inc. director, president and CEO Marshall Fordyce reported open-market sales of a total of 18,500 shares of Class A Common Stock on June 23, 2026. The sales were executed at weighted-average prices of $38.43 and $37.93 per share.
The filing states these transactions were made under a pre-arranged Rule 10b5-1(c) trading plan adopted on January 9, 2026, with individual trades occurring between $37.43 and $38.315. After the sales, Fordyce directly holds 198,244 shares and indirectly holds 99,081 shares through a trust and 122,949 shares through a GRAT.
VERA notice reports an intended resale of 74,000 shares via an exercise of stock options on 06/23/2026. The filing also discloses prior 10b5-1 sales by Marshall Fordyce of 18,500 shares on 05/12/2026 and 22,951 shares on 04/14/2026.
Vera Therapeutics reported a key regulatory update for its drug candidate atacicept in adults with IgA nephropathy. The company has aligned with the U.S. Food and Drug Administration on a revised, earlier ORIGIN 3 eGFR analysis plan intended to support potential full approval.
The eGFR results from ORIGIN 3 are now expected in the third quarter of 2026. If those results are supportive, Vera plans to submit a supplemental Biologics License Application for full approval of atacicept in the fourth quarter of 2026. The company cautions that these are forward-looking statements subject to clinical, regulatory, and broader business risks.
Vera Therapeutics, Inc. reported results from its 2026 Annual Meeting of Stockholders. As of the March 24, 2026 record date, 71,713,905 shares of Class A common stock were outstanding and entitled to vote.
Stockholders elected three Class II directors to terms ending at the 2029 annual meeting: Michael M. Morrisey, Ph.D. (45,288,710 votes for, 13,814,671 withheld, 2,863,469 broker non-votes), Patrick G. Enright (54,697,296 for, 4,406,085 withheld, 2,863,469 broker non-votes), and James R. Meyers (58,946,269 for, 157,112 withheld, 2,863,469 broker non-votes).
Stockholders also ratified KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 61,834,842 votes for, 44,710 against, and 87,298 abstentions. In an advisory vote, stockholders approved executive compensation, with 56,585,568 votes for, 2,433,537 against, 84,276 abstentions, and 2,863,469 broker non-votes.
Vera Therapeutics director Scott W. Morrison received a grant of stock options covering 17,084 shares of Class A common stock. The options have an exercise price of $34.35 per share and vest in full on the earlier of the first anniversary of the grant date or the company’s 2027 annual stockholder meeting, or sooner upon a change in control, subject to his continued service. After this grant, he holds options on 17,084 shares directly.
Vera Therapeutics director Andrew Cheng received a new stock option grant as part of his compensation. On the grant date, he was awarded options covering 17,084 shares of Class A Common Stock with an exercise price of $34.35 per share, all held directly.
The option vests in full on the earlier of the first anniversary of the grant date or the company’s 2027 annual stockholder meeting, provided he remains in continuous service. It will also fully vest upon a change in control if he is still serving at that time. After this grant, he holds options for 17,084 shares, expiring in 2036.